DOCSLIB.ORG

Age, HLA, and Sex Define a Marked Risk of Organ-Specific

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Age, HLA, and Sex Define a Marked Risk of Organ-Specific Diabetes Care 1 fi Christiane Winkler,1,2 Manja Jolink,1 Age, HLA, and Sex De ne a Annette Knopff,1 Nana-Adjoa Kwarteng,1 fi Peter Achenbach,1,2,3 Ezio Bonifacio,4,5 and Marked Risk of Organ-Speci c Anette-G. Ziegler1,2,3 Autoimmunity in First-Degree Relatives of Patients With Type 1 Diabetes https://doi.org/10.2337/dc19-0315 EPIDEMIOLOGY/HEALTH SERVICES RESEARCH OBJECTIVE Autoimmune diseases can be diagnosed early through the detection of autoanti- bodies. The aim of this study was to determine the risk of organ-specific autoimmunity in individuals with a family history of type 1 diabetes. RESEARCH DESIGN AND METHODS The study cohort included 2,441 first-degree relatives of patients with type 1 diabetes who were prospectively followed from birth to a maximum of 29.4 years (median 13.2 years). All were tested regularly for the development of autoanti- 1Institute of Diabetes Research, Helmholtz bodies associated with type 1 diabetes (islet), celiac disease (transglutaminase), or Zentrum Munchen,¨ German Research Center for Environmental Health, Munich-Neuherberg, thyroid autoimmunity (thyroid peroxidase). The outcome was defined as an Germany autoantibody-positive status on two consecutive samples. 2Forschergruppe Diabetes e.V. at Helmholtz Zentrum Munchen,¨ German Research Center RESULTS for Environmental Health, Munich-Neuherberg, In total, 394 relatives developed one (n = 353) or more (n = 41) of the three disease- Germany 3Forschergruppe Diabetes, Technical University associated autoantibodies during follow-up. The risk by age 20 years was 8.0% (95% Munich at Klinikum rechts der Isar, Munich, CI 6.8–9.2%) for islet autoantibodies, 6.3% (5.1–7.5%) for transglutaminase auto- Germany 4 antibodies, 10.7% (8.9–12.5%) for thyroid peroxidase autoantibodies, and 21.5% Center for Regenerative Therapies Dresden, – Faculty of Medicine, Technical University Dres- (19.5 23.5%) for any of these autoantibodies. Each of the three disease-associated den, Dresden, Germany autoantibodies was defined by distinct HLA, sex, genetic, and age profiles. The risk of 5Paul Langerhans Institute Dresden of the Helm- developing any of these autoantibodies was 56.5% (40.8–72.2%) in relatives with holtz Center Munich at University Hospital Carl HLA DR3/DR3 and 44.4% (36.6–52.2%) in relatives with HLA DR3/DR4-DQ8. Gustav Carus and Faculty of Medicine, Technical University Dresden, Dresden, Germany CONCLUSIONS Corresponding author: Anette-G. Ziegler, anette-g Relatives of patients with type 1 diabetes have a very high risk of organ-specific [email protected] autoimmunity. Appropriate counseling and genetic and autoantibody testing for Received 15 February 2019 and accepted 31 May 2019 multiple autoimmune diseases may be warranted for relatives of patients with This article contains Supplementary Data online type 1 diabetes. at http://care.diabetesjournals.org/lookup/suppl/ doi:10.2337/dc19-0315/-/DC1. Prospective studies that follow children from birth have established that autoim- C.W. and M.J. share first authorship. munity can start very early in life and years before clinical symptoms appear (1–3). In © 2019 by the American Diabetes Association. type 1 diabetes, autoimmunity often appears between 6 months and 3 years of age Readers may use this article as long as the work – is properly cited, the use is educational and not (1 3), and the large majority of children who develop autoantibodies against multiple for profit, and the work is not altered. More infor- pancreatic islet antigens at this age progress to clinical disease (4). New disease mation is available at http://www.diabetesjournals paradigms have emerged from such studies, leading to extensive screening (5), the .org/content/license. Diabetes Care Publish Ahead of Print, published online June 18, 2019 2 Familial Risks of Autoantibodies Diabetes Care investigation of potential causes of the to gluten reduces the risk of developing Outcome Definition diseases (6), and consortia that attempt autoantibodies. That intervention failed IA positivity was defined as the devel- to prevent disease in asymptomatic in- to show any effect on autoantibody de- opment of persistent IAA, GADA, IA-2A, dividuals (7). velopment, and all the participants con- or zinc transporter 8, with sample The BABYDIAB and subsequent BABY- tinued with follow-up examinations values .99th percentile of control chil- DIET studies were the first of these pro- according to the natural history protocol dren. Persistence was defined as auto- spective from-birth studies of type 1 (8). The studies were approved by the antibody positivity in at least two diabetes (8,9). These studies have ethics committees of Bavaria, Germany consecutive samples or in the last sample been following newborn children who (Bayerische Landesarztekammer¨ no. if the participant developed diabetes have a first-degree relative with type 1 95357 and Ludwig-Maximilians Univer- before providing a follow-up sample. diabetes on the basis that they have an sity no. 329/00, respectively) and were The age at the first IA-positive sample elevated risk of developing the disease. performed in accordance with the prin- was considered the age of seroconver- Over the course of follow-up, the chil- ciples of the Declaration of Helsinki, in- sion. The children were classified as dren were also observed to be at risk for cluding the provision of written informed multiple-IA positive if in addition to developing other autoantibodies (10,11), consent from all participants or their persistent IA positivity they tested pos- similar to findings in patients with type 1 parents. itive for more than one of the IAs on at diabetes (12–15) and in their family Children were scheduled for follow- least one occasion. In children who were members (16–18). The participants in up and venous blood collection at ages positive for GADA in the absence of other these studies are now approaching 9 months, 2 years, and every 3 years IAs, GADA was also assessed for its GAD- 30 years of age and provide a unique thereafter, and for the 150 children who binding affinity (19) and positivity on an opportunity to track the course of auto- participated in the dietary intervention, ELISA (Medizym anti-GAD ELISA Kit; immunity from birth to adulthood. The every 3 months until 3 years of age and MEDIPAN, Berlin, Germany). These chil- aim of the current study was to deter- yearly thereafter. The median follow-up dren were classified as single-GADA pos- mine the risk of organ-specific autoim- period from birth to the last sample itiveiftheyhadGADAwithaffinity $109 munity in individuals with a family history was 13.2 years (interquartile range L/mol or tested positive on the radio- of type 1 diabetes. Our findings demon- [IQR] 7.4–18.2 years) and from birth to binding assay and ELISA measurements strate distinct age, sex, and genetic pro- the last contact was 16.1 years (11.2–20.0 (21). In children who were positive for files for the autoantibodies associated years). IAA in the absence of other IAs, IAAs were with the three diseases examined, which assessed for their insulin-binding affinity occur with surprisingly high frequency Autoantibody Measurements and were classified as single-IAA positive in first-degree relatives of patients with Thetype1diabetes–associated islet if they had IAA with affinity $109 L/mol type 1 diabetes. Our findings are relevant autoantibodies (IAs) against insulin (19). TGA positivity was defined as the to the causes of autoimmunity and (IAA), GAD (GADA), IA2 (IA-2A), and development of persistent antibodies provide a strong rationale and prac- zinc transporter 8 were measured at above a threshold representing the tical guidelines for autoantibody testing the Helmholtz Center, Munich, Germany, 99th percentile of control children in members of families affected by type in venous blood samples obtained at all (10,11). TPOA positivity was defined as 1 diabetes. completed visits. The celiac disease– the development of persistent antibod- associated IgA autoantibodies against ies above a threshold of 50 units/mL, as RESEARCH DESIGN AND METHODS tissue transglutaminase 2 (TGA) and the defined with a quantile-quantile plot Study Population thyroid autoimmune disease–associated analysis (11). For TPOA and TGA, persis- Data from two German birth cohorts of autoantibodies against thyroid peroxi- tence was defined as a positive result in individuals with a first-degree family dase (TPOA) were not measured in two consecutive samples or autoanti- history of type 1 diabetes born between 46 and 30 children, respectively, because body levels of .10 units/mL (TGA) 1989 and 2000 (BABYDIAB) or between of insufficient sample volume. Measure- or .100 units/mL (TPOA) in the last 2000 and 2006 (BABYDIET) were com- ments were made with radiobinding measured sample if a second sample bined and analyzed (8,9). Both studies assays (10,11,19,20). The IA assays was unavailable for testing. prospectively examined the natural his- (laboratory 121) were evaluated in the Type 1 diabetes was diagnosed accord- tory of islet autoimmunity and type 1 Diabetes Autoantibody Standardiza- ing to the criteria of the American Di- diabetes, celiac disease–associated au- tion Program, which included other abetes Association Expert Committee toimmunity, and thyroid autoimmunity. assays that gave similar performances (26). Families were asked to report The BABYDIAB study recruited 1,650 (21–23). The genetic typing at the the occurrence of diabetes symptoms. infants born to a mother or father HLA-DRB1, HLA-DQA1, and HLA-DQB1 InchildrenwithIAs,anannualoral with type 1 diabetes, and the BABYDIET loci and at single nucleotide poly- glucose tolerance test was performed. study recruited 791 infants who had a morphisms (SNPs) rs689 (INS gene), Type 1 diabetes onset was defined as mother, father, or sibling with type 1 rs2476601 (PTPN22 gene), rs1990760 unequivocal hyperglycemia with acute diabetes. A subgroup of 150 children (IFIH1 gene), and rs3184504 (SH2B3 metabolic decompensation, the obser- participated in the BABYDIET gluten gene) was performed in 2,290 children vation on at least two occasions of a 2-h intervention study (Clinical trial reg.
Load more

Recommended publications
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases
    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
    [Show full text]
  • Autoantibody Development Under Treatment with Immune-Checkpoint Inhibitors Emma C
    Published OnlineFirst November 13, 2018; DOI: 10.1158/2326-6066.CIR-18-0245 Cancer Immunology Miniature Cancer Immunology Research Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors Emma C. de Moel1, Elisa A. Rozeman2, Ellen H. Kapiteijn3, Els M.E. Verdegaal3, Annette Grummels4,JaapA.Bakker4, Tom W.J. Huizinga1, John B. Haanen2,3, Rene E.M. Toes1, and Diane van der Woude1 Abstract Immune-checkpoint inhibitors (ICIs) activate the and any irAEs [OR, 2.92; 95% confidence interval (CI) immune system to assault cancer cells in a manner that is 0.85–10.01]. Patients with antithyroid antibodies after ipi- not antigen specific. We hypothesized that tolerance may limumab had significantly more thyroid dysfunction under also be broken to autoantigens, resulting in autoantibody subsequent anti–PD-1 therapy: 7/11 (54.6%) patients with formation, which could be associated with immune-related antithyroid antibodies after ipilimumab developed thyroid adverse events (irAEs) and antitumor efficacy. Twenty-three dysfunction under anti–PD1 versus 7/49 (14.3%) patients common clinical autoantibodies in pre- and posttreatment without antibodies (OR, 9.96; 95% CI, 1.94–51.1). Patients sera from 133 ipilimumab-treated melanoma patients were who developed autoantibodies showed a trend for better determined, and their development linked to the occurrence survival (HR for all-cause death: 0.66; 95% CI, 0.34–1.26) of irAEs, best overall response, and survival. Autoantibodies and therapy response (OR, 2.64; 95% CI, 0.85–8.16). We developed in 19.2% (19/99) of patients who were autoan- conclude that autoantibodies develop under ipilimumab tibody-negative pretreatment.
    [Show full text]
  • Tests for Autoimmune Diseases Test Codes 249, 16814, 19946
    Tests for Autoimmune Diseases Test Codes 249, 16814, 19946 Frequently Asked Questions Panel components may be ordered separately. Please see the Quest Diagnostics Test Center for ordering information. 1. Q: What are autoimmune diseases? A: “Autoimmune disease” refers to a diverse group of disorders that involve almost every one of the body’s organs and systems. It encompasses diseases of the nervous, gastrointestinal, and endocrine systems, as well as skin and other connective tissues, eyes, blood, and blood vessels. In all of these autoimmune diseases, the underlying problem is “autoimmunity”—the body’s immune system becomes misdirected and attacks the very organs it was designed to protect. 2. Q: Why are autoimmune diseases challenging to diagnose? A: Diagnosis is challenging for several reasons: 1. Patients initially present with nonspecific symptoms such as fatigue, joint and muscle pain, fever, and/or weight change. 2. Symptoms often flare and remit. 3. Patients frequently have more than 1 autoimmune disease. According to a survey by the Autoimmune Diseases Association, it takes up to 4.6 years and nearly 5 doctors for a patient to receive a proper autoimmune disease diagnosis.1 3. Q: How common are autoimmune diseases? A: At least 30 million Americans suffer from 1 or more of the 80 plus autoimmune diseases. On average, autoimmune diseases strike three times more women than men. Certain ones have an even higher female:male ratio. Autoimmune diseases are one of the top 10 leading causes of death among women age 65 and under2 and represent the fourth-largest cause of disability among women in the United States.3 Women’s enhanced immune system increases resistance to infection, but also puts them at greater risk of developing autoimmune disease than men.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • Systemic Lupus Erythematosus T Cell Studies in a Peptide-Induced Model Of
    T Cell Studies in a Peptide-Induced Model of Systemic Lupus Erythematosus Magi Khalil, Kayo Inaba, Ralph Steinman, Jeffrey Ravetch and Betty Diamond This information is current as of September 25, 2021. J Immunol 2001; 166:1667-1674; ; doi: 10.4049/jimmunol.166.3.1667 http://www.jimmunol.org/content/166/3/1667 Downloaded from References This article cites 73 articles, 40 of which you can access for free at: http://www.jimmunol.org/content/166/3/1667.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. T Cell Studies in a Peptide-Induced Model of Systemic Lupus Erythematosus Magi Khalil,* Kayo Inaba,‡ Ralph Steinman,‡ Jeffrey Ravetch,‡ and Betty Diamond1† We have previously reported that immunization with a peptide mimetope of dsDNA on a branched polylysine backbone (DWEYSVWLSN-MAP) induces a systemic lupus erythematosus-like syndrome in the nonautoimmune BALB/c mouse strain.
    [Show full text]
  • Allogeneic Red Blood Cell Adsorption for Removal of Warm Autoantibody
    Allogeneic red blood cell adsorption for removal of warm autoantibody C. Barron Adsorption studies are usually required to confirm or rule out Reagents/Supplies the presence of underlying alloantibodies in samples containing warm autoantibody. Allogeneic adsorptions are necessary if the Treatment patient has been recently transfused. Most commonly, allogeneic Method Reagents Supplies adsorptions are performed using a trio of phenotyped reagent Papain • 1% cysteine-activated red blood cells to rule out clinically significant alloantibodies to papain common antigens. The adsorbing cells may be used untreated • Pipettes or treated with enzymes or with ZZAP before adsorption. Ficin • 1% ficin • Isotonic • 37°C water Adsorption may also be performed using enhancement such ZZAP • 1% cysteine-activated saline bath SEROLOGIC METHOD REVIEW as low-ionic strength saline or polyethylene glycol added to papain or 1% ficin • Allogeneic the mixture. Multiple adsorptions may be necessary to remove RBCs • Large-bore • 0.2 M DTT test tubes strongly reactive autoantibodies. Allogeneic adsorptions • Glycine max • Commercial LISS will not detect alloantibodies to high-prevalence antigens. var. soja • Calibrated enhancement reagent centrifuge Immunohematology 2014;30:153–155. • 20% PEG or commercial PEG enhancement Key Words: AIHA, adsorption, autoantibody, alloantibody, DTT = dithiothreitol; RBCs = red blood cells; LISS = low-ionic-strength allogeneic RBCs saline; PEG = polyethylene glycol. The serum from patients with warm autoimmune Procedural Steps hemolytic anemia (WAIHA) typically demonstrates broad Preparation of RBCs for adsorption reactivity with all reagent red blood cells (RBCs). This • Select reagent RBCs for use as adsorbing cells. reactivity usually necessitates the use of incompatible blood for • Treat the adsorbing cells with the desired enzyme or ZZAP.
    [Show full text]
  • I M M U N O L O G Y Core Notes
    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111
    [Show full text]
  • Correlation Between Warm Reactive Autoantibodies and the Monocyte
    Correlation Between Warm Reactive Autoantibodies And The Monocyte Monolayer Assay 1 ABSTRACT BACKGROUND: The monocyte monolayer assay (MMA) measures the adherence and phagocytosis of sensitized red cells with peripheral monocytes. The result of MMA therefore may reflect to some extent the in vivo destruction of sensitized red blood cells (RBCs). However, serological and clinical features of patients with warm reactive autoantibodies do not always show strict correlation with in vivo activity. To evaluate the correlation of warm reactive autoantibody between the MMA result and the clinical data may add value in distinguishing whether or not the autoantibodies are harmful. STUDY DESIGN AND METHODS: Blood samples from 20 patients with warm reactive autoantibodies were investigated using the MMA. The Monocyte Index (MI) values > 5% were considered positive while MI values ≤ 5% were considered negative. RESULTS: Of the 20 patients, only one patient had a positive MMA result with an MI of 30%. All other 19 patients demonstrated a negative MI value (<5%). There was no correlation between serologically detectable warm reactive autoantibodies and the MMA or DAT. CONCLUSION: Our findings were only a preliminary study; the final conclusion demands more comparative studies between the clinical and serologic features of patients with warm autoantibodies and the MMA tests. The mechanism of red cell destruction depends on many factors. Furthermore, there are many variables that exist within the MMA which may have an effect on the outcome. These variables should be taken into account when interpreting MMA results. 2 INTRODUCTION Warm reactive autoantibodies are red blood cell (RBC) directed immune responses that are maximally reactive at 37°C.
    [Show full text]
  • Autoantibody-Boosted T-Cell Reactivation in the Target Organ Triggers Manifestation of Autoimmune CNS Disease
    Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease Anne-Christine Flacha,1, Tanja Litkea,1, Judith Straussa,1, Michael Haberla, César Cordero Gómeza, Markus Reindlb, Albert Saizc, Hans-Jörg Fehlingd, Jürgen Wienandse, Francesca Odoardia, Fred Lühdera,2, and Alexander Flügela,f,2,3 aInstitute of Neuroimmunology and Institute for Multiple Sclerosis Research, University Medical Centre Göttingen, D-37073 Göttingen, Germany; bClinical Department of Neurology, Medical University of Innsbruck, A-6020 Innsbruck, Austria; cService of Neurology, Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer Casanova, E-08028 Barcelona, Spain; dInstitute for Immunology, University of Ulm, D-89081 Ulm, Germany; eInstitute for Cellular and Molecular Immunology, University Medical Centre Göttingen, D-37073 Göttingen, Germany; and fMax-Planck-Institute for Experimental Medicine Göttingen, D-37075 Göttingen, Germany Edited by Harvey Cantor, Dana-Farber Cancer Institute, Boston, MA, and approved February 5, 2016 (received for review October 4, 2015) Multiple sclerosis (MS) is caused by T cells that are reactive for structural damage in autoimmune CNS lesions (18, 19). Part of brain antigens. In experimental autoimmune encephalomyelitis, the puzzle is that B cells have also been observed to have a the animal model for MS, myelin-reactive T cells initiate the auto- disease-dampening effect via their release of antiinflammatory immune process when entering the nervous tissue and become cytokines, specifically IL-10 and/or IL-35 (20, 21). reactivated upon local encounter of their cognate CNS antigen. Using an integrative approach of intravital imaging, genetics, Thereby, the strength of the T-cellular reactivation process within and functional characterization, we here studied the interactions the CNS tissue is crucial for the manifestation and the severity of the of T and B cells in the course of EAE.
    [Show full text]
  • A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy
    antibodies Review A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy Payal M. Patel 1,2 , Virginia A. Jones 1 , Christy T. Behnam 1, Giovanni Di Zenzo 3 and Kyle T. Amber 2,4,* 1 Department of Dermatology, University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA; [email protected] (P.M.P.); [email protected] (V.A.J.); [email protected] (C.T.B.) 2 Rush University Medical Center, Division of Dermatology, Department of Otorhinolaryngology—Head and Neck Surgery, Rush University, Chicago, IL 60612, USA 3 Laboratory of Molecular and Cell Biology, IDI-IRCCS, 00167 Rome, Italy; [email protected] 4 Rush University Medical Center, Department of Internal Medicine, Rush University, Chicago, IL 60612, USA * Correspondence: [email protected] Abstract: Gene therapy serves as a promising therapy in the pipeline for treatment of epidermolysis bullosa (EB). However, with great promise, the risk of autoimmunity must be considered. While EB is a group of inherited blistering disorders caused by mutations in various skin proteins, autoimmune blistering diseases (AIBD) have a similar clinical phenotype and are caused by autoantibodies targeting skin antigens. Often, AIBD and EB have the same protein targeted through antibody or mutation, respectively. Moreover, EB patients are also reported to carry anti-skin antibodies of questionable pathogenicity. It has been speculated that activation of autoimmunity is both a consequence and cause of further skin deterioration in EB due to a state of chronic inflammation. Citation: Patel, P.M.; Jones, V.A.; Behnam, C.T.; Zenzo, G.D.; Amber, Herein, we review the factors that facilitate the initiation of autoimmune and inflammatory responses K.T.
    [Show full text]
  • Warm Autoadsorption: Are We Wasting Our Time?
    Warm Autoadsorption: Are We Wasting Our Time? 1 Warm Autoadsorption: Are We Wasting Our Time? Abstract BACKGROUND: Routine adsorption procedures to remove autoantibodies from patient’s serum often require many hours. This time-consuming process can create significant delays impacting patient care. This study modified the current adsorption method to reduce total adsorption time to one hour. STUDY DESIGN AND METHODS: A ratio of one part serum to three parts RBCs (1:3 Method) was maintained for all samples. The one part serum was split into three tubes. Each aliquot of serum was mixed with one full part RBCs, creating three adsorbing tubes. All tubes were incubated for one hour with periodic mixing. Adsorbed serum from each tube was harvested, combined and tested for reactivity. RESULTS: Fifty-eight samples were evaluated using the routine method and the 1:3 Method. Forty-eight (83%) cases successfully adsorbed using both methods. Twenty (34.5%) cases contained underlying alloantibodies. The 1:3 Method demonstrated the same antibody specificities and strengths in all 20 cases. Eight cases failed to adsorb by both methods. The 1:3 Method found previously undetected alloantibodies in three cases. Two cases successfully autoadsorbed but failed to alloadsorb by both methods. CONCLUSION: The 1:3 Method proved to be efficient and effective for quick removal of autoantibodies while allowing for the detection of underlying alloantibodies. 2 INTRODUCTION Red blood cell (RBC) autoantibodies, when present in the serum of a patient, will react with the patient’s RBCs as well as all normal RBCs. These autoantibodies have the potential of masking the presence of underlying clinically significant alloantibodies.
    [Show full text]
  • Chapter 15 the Natural Autoantibody Repertoire In
    CHAPTER 15 THE NATURAL AUTOANTIBODY REPERTOIRE IN NEWBORNS AND ADULTS: A Current Overview Asaf Madi,1,2 Sharron Bransburg-Zabary,1,2 Dror Y. Kenett,2 Eshel Ben-Jacob*,2,3 and Irun R. Cohen*,4 1Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel; 3The Center for Theoretical and Biological Physics, University of California San Diego, La Jolla, California, USA; 4Department of Immunology, Weizmann Institute of Science, Rehovot, Israel *Corresponding Author: Irun R. Cohen—Email: [email protected] Abstract: Antibody networks have been studied in the past based on the connectivity between idiotypes and anti-idiotypes—antibodies that bind one another. Here we call attention to a different network of antibodies, antibodies connected by their reactivities to sets of antigens—the antigen-reactivity network. The recent development of antigen microarray chip technology for detecting global patterns of antibody reactivities makes it possible to study the immune system quantitatively using network analysis tools. Here, we review the analyses of IgM and IgG autoantibody reactivities of sera of mothers and their offspring (umbilical cords) to 300 defined self-antigens; the autoantibody reactivities present in cord blood represent the natural autoimmune repertories with which healthy humans begin life and the mothers’ reactivities reflect the development of the repertoires in healthy young adults. Comparing the cord and maternal reactivities using several analytic tools led to the following conclusions: (1) The IgG repertoires showed a high correlation between each mother and her newborn; the IgM repertoires of all the cords were very similar and each cord differed from its mother’s IgM repertoire.
    [Show full text]